TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01927458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
Study: NCT04248777

Intervention type: OTHER
Group type: OTHER
Intervention: standardised OCT-guided intervention
Description: The first OCT run (run1) analyse plaque characteristics, identify proximal and distal landing zones (according to previously published criteria) , measure lesion length and reference segments dimensions (diameters and luminal areas). The second run (run2) aims to assess adequate guidewire recrossing point into stent jailed side branch and identify early stent mechanical non-optimal results. The third run (run3) analyse final stent expansion and identify major struts malposition and edge dissection.
Study: NCT03938246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640 25 mg (US)
Description: Oral dose, tablet, daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640 50 mg (US)
Description: Oral dose, tablet, daily dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (US)
Description: Oral dose, tablet, daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640 50 mg (China)
Description: Oral dose, tablet, daily dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (China)
Description: Oral dose, tablet, daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640 75 mg (US)
Description: Oral dose, tablet, daily dosing
Study: NCT04284319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCD Heart Transplantation Using NRP
Description: Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)
Study: NCT01787565

Intervention type: OTHER
Intervention: painPREMIER cohort
Description: Low back pain patients prospectively recruited during the study period and managed with painPREMIER.

Intervention type: OTHER
Intervention: Control cohort
Description: A matched group of low back pain patients not managed with painPREMIER.
Study: NCT01838681

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADT
Description: Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
Study: NCT04363554

Intervention type: OTHER
Group type: OTHER
Intervention: Fluid intake
Description: The participants will intake fluid

Intervention type: OTHER
Group type: OTHER
Intervention: Thirsting
Description: The participants will thirst
Study: NCT02016274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy
Description: Sequential paclitaxel/cisplatin chemotherapy and radiotherapy
Study: NCT01406353

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Mitral Commissurotomy
Description: Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area \> 1.5 square cm with less than moderate to severe mitral regurgitation.
Study: NCT00298415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatin
Description: Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monotherapy (gemcitabine or vinorelbine)
Description: Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
Study: NCT02067611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002
Description: Parallel Assignment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parallel Assignment
Study: NCT01852487

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 400mg /day during 6 months
Study: NCT03340623

Intervention type: DEVICE
Intervention: Venous coupler
Description: A coupler can be used to perform a venous anastomosis. It is a double ring with pins on only one of its 2 faces. The technique consists in clamping the two veins, estimating the intima-to-intimal diameter of the vessels, choosing the coupler of the appropriate size, sliding the vein in the ring and evers the edges of the vessel to fix them on the pins, redo the same thing for the other vein and finally bring the two vessels together in order to clip them together.
Study: NCT00815087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Description: 15 sessions of VitalStim® therapy, 60 minutes per session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise home program
Description: Daily exercise training
Study: NCT04913974

Intervention type: PROCEDURE
Intervention: Uni-condylar knee arthroplasty
Description: Surgical replacement of medial compartment of arthritic knee with an implant
Study: NCT06603532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-load blood flow restriction (BFR) training
Description: The training program lasted four weeks with three training sessions per week, for a total of 12 training sessions. Participants in the BFR group exercised with blood flow restriction caused by an inflatable cuff placed on the proximal part of the thigh and inflated to 120-140 mmHg. Subjects trained against the maximum mechanical resistance they could overcome thirty times (30 repetitions maximum; 30 RM). All training sessions were performed under the supervision of a physiotherapist and included leg press and knee extension exercises.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: low-load resistance training
Description: The training program lasted four weeks with three training sessions per week, for a total of 12 training sessions. Participants in SHAM-BFR group performed an identical exercise protocol as experimental (BFR) group, while having thigh cuff inflated to only 20 mmHg, which did not affect normal muscle blood flow. Subjects trained against the maximum mechanical resistance they could overcome thirty times (30 repetitions maximum; 30 RM). All training sessions were performed under the supervision of a physiotherapist and included leg press and knee extension exercises.
Study: NCT03333538

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamEvac-Lyo (component A)
Description: Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component A

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamEvac-Lyo (component B)
Description: Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamEvac-Lyo
Description: Biological: GamEvac-Lyo (vaccine) vaccination, therapeutic scheme: the sequential introduction of components A and b with an interval of 21 days
Study: NCT00711568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: 20 Hz rTMS delivered for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli (25 minutes)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: 20 Hz rTMS delivered for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli (25 minutes)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: 20 Hz sham rTMS delivered to L or R frontal region for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulator
Description: Repetitive Transcranial Magnetic Stimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulator
Description: Repetitive Transcranial Magnetic Stimulator
Study: NCT02482467

Intervention type: OTHER
Group type: OTHER
Intervention: Hormonal analysis, pelvic US

Intervention type: OTHER
Group type: OTHER
Intervention: Hormonal analysis, pelvic US
Study: NCT02828501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: A spinal manipulation is a high velocity, low amplitude thrust through a physiological barrier in order to elicit a cavitation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: A spinal manipulation is a high velocity, low amplitude thrust through a physiological barrier in order to elicit a cavitation.
Study: NCT01145222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C. CNS 7056
Description: Initial high dose plus supplemental doses as necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D. Midazolam
Description: Initial standardized dose plus supplemental doses as necessary.
Study: NCT02100917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMB-3111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Study: NCT01913405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant factor VIII (rFVIII)
Description: Lyophilized powder and solvent for solution for injection
Study: NCT02343328

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fecal Microbiota Transplant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01967953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVLP Group
Description: EVLP technique: Steen solution; normothermia; low flow, open atrium, low hematocrit.~Endpoints of EVLP assessment of lungs suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
Study: NCT03640182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health management model of TCM preventive medicine
Description: The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
Study: NCT00508300

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Epidural analgesia
Description: Thoracic epidural analgesia until day 2

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Patient controlled analgesia
Description: Patient controlled analgesia (morphine-based)
Study: NCT00132483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instruction in physical training program
Description: Instruction in physical training program.
Study: NCT02715752

Intervention type: DIETARY_SUPPLEMENT
Intervention: Gene-Eden-VIR/Novirin

Intervention type: DIETARY_SUPPLEMENT
Intervention: Gene-Eden-VIR/Novirin

Intervention type: DIETARY_SUPPLEMENT
Intervention: Gene-Eden-VIR/Novirin

Intervention type: DIETARY_SUPPLEMENT
Intervention: Gene-Eden-VIR/Novirin

Intervention type: DIETARY_SUPPLEMENT
Intervention: Gene-Eden-VIR/Novirin
Study: NCT04352660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C injection
Description: MMC delivered by preoperative subconjunctival injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C sponge
Description: MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
Study: NCT04425850

Intervention type: COMBINATION_PRODUCT
Intervention: Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)
Description: Topical application in the nose and oral cavity
Study: NCT03280862

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator
Description: Implantation of CRT-P/-D device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator
Description: Implantation of CRT-P/-D device
Study: NCT00545805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass plus total omentectomy
Description: Roux-en-Y Gastric Bypass plus total omentectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass
Description: Roux-en-Y Gastric Bypass without omentectomy
Study: NCT01746056

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusive Heat Patch
Description: The heat patch will be applied for 2 hours every day for a period of 12 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusive Heat Patch
Description: The heat patch will be applied for 2 hours every day for a period of 12 weeks.
Study: NCT02995720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan/Amlodipine combination drug, Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan/Amlodipine combination drug, Rosuvastatin
Study: NCT03923660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental Concentric-eccentric exercise test
Description: Patients will perform incremental exercise test on semi recumbent eccentric ergometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental Eccentric-concentric exercise test
Description: Patients will perform incremental exercise test on semi recumbent concentric ergometer
Study: NCT03711760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telepsychology
Description: CBT delivered by telepsychology
Study: NCT03094598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leaflet
Description: The length is 1.5 A4 pages, Flesch's Reading Ease Score (RES) is 57 (fairly difficult, comparable to a quality magazine), and Human Interest Score (HIS) is 37 (interesting, comparable to a digest magazine).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brochure
Description: The length is 2.5 A4 pages, RES is 43 (difficult, comparable to an academic magazine), and HIS is 25 (interesting, comparable to a digest magazine).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet
Description: The length is 12 A4 pages, RES is 11 (very difficult, comparable to a scientific magazine), and HIS is 22 (mildly interesting, comparable to a trade magazine).
Study: NCT00428298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Subjects take two 500 mg capsules twice daily for 16 weeks.
Study: NCT01009112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD + IRT/CBT-I
Description: 6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD + IRT/CBT-I
Description: 6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD + IRT/CBT-I
Description: 6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD + Supportive Care Therapy
Description: 6 weeks of prolonged exposure + 12 weeks of supportive care therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PTSD + Supportive Care Therapy
Description: 6 weeks of prolonged exposure + 12 weeks of supportive care therapy
Study: NCT01166269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: phleum pratense (grass-allergen)
Description: 6 injections of grass-allergen. Every dose will be 1000 SQ-U.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: phleum pratense (grass allergen)
Description: 3 injections of grass-allergen. Every dose will be 1000 SQ-U. Also 3 injections of placebo (physiological saline)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: 6 injections of placebo (physiological saline)in a lymph node.
Study: NCT00005963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT00643045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide
Study: NCT02614014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior interventional program
Study: NCT01623752

Intervention type: DRUG
Intervention: Etanercept
Description: The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

Intervention type: DRUG
Intervention: Etanercept
Description: The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study: NCT01814332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK561679
Description: GSK561679, oral administration, 350mg/day, 6 week administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo compound treatment for comparison with IP
Study: NCT03233685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Training
Description: The visual training will be performed 3 times a week for 40 minutes, at the end of warm up and before the technique training. The subjects will be performed a progression of exercise to improve their visual ability, their velocity of interpretation and transformation. The training will be performed with specific panels approved for visual training (S.V.T.A., Torino, Italy).
Study: NCT00799175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine, ketorolac and epinephrine
Description: In Group A, 400 mg ropivicaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue. After 21 postoperative hours in Group A, 200 mg ropivicaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: In Group P (placebo) no injections were given intraoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
Study: NCT00643045

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02559505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal IIV 0.25 mL dose
Description: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal IIV 0.25 mL dose
Description: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural influenza infection
Description: Children enrolled on presentation to their primary care provider with a natural influenza infection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural influenza infection
Description: Children enrolled on presentation to their primary care provider with a natural influenza infection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural influenza infection
Description: Children enrolled on presentation to their primary care provider with a natural influenza infection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural influenza infection
Description: Children enrolled on presentation to their primary care provider with a natural influenza infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal IIV 0.5 mL dose
Description: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal IIV 0.5 mL dose
Description: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal IIV 0.5 mL dose
Description: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal IIV 0.5 mL dose
Description: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal IIV 0.5 mL dose
Description: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal IIV 0.5 mL dose
Description: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
Study: NCT02537860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paravertebral block injections from T12 to L2
Description: Three anesthetic injections are done
Study: NCT03233685

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Training
Description: Normal training routine